XP-006 vaccine study for relapsed B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests an experimental mRNA vaccine (XP-006) for patients with B-cell non-Hodgkin lymphoma that has come back or not responded to prior treatment. It aims to see if the vaccine can help the immune system fight the lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have B-cell non-Hodgkin lymphoma that has relapsed or didn't respond to at least one prior treatment.
- You have a specific gene mutation and blood type (HLA type) that matches the vaccine requirements.
- You have at least one tumor that can be seen on a PET/CT scan.
- Your major organs (like liver, kidneys, heart) are working well enough based on blood tests.
- You are not pregnant or breastfeeding, and do not have active hepatitis B, C, or HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new mRNA treatment that helps your immune cells target and attack lymphoma cells. It's for people whose B-cell non-Hodgkin lymphoma has come back or not responded to prior treatments.
This trial tests an experimental mRNA vaccine designed to target cancer cells infected with the Epstein-Barr virus (EBV). It is for people with certain types of lymphoma that have come back or not responded to standard treatments. The goal is to see if the vaccine can help the immune system fight the cancer.
This trial tests a new cell therapy called CT1190B for people with certain types of B-cell lymphoma that have come back or not responded to at least two prior treatments. It aims to see if this therapy can help control the cancer.
This trial tests an investigational cell therapy that targets two markers (CD20 and CD19) on your lymphoma cells. It may be an option if your B-cell lymphoma has come back or not responded to prior treatments.
This early-stage trial tests a new drug called GSK5926371 in adults whose B-cell lymphoma (a blood cancer) has come back or stopped responding to previous treatments. The study aims to find out if this drug is safe and whether it can help shrink the cancer.
This trial tests an experimental drug, SAR448501/DR-0201, for people with B-cell non-Hodgkin lymphoma that has come back or not responded to at least two prior treatments. The goal is to see if the drug is safe and can shrink tumors.
Hear when a new B-cell Non-Hodgkin's Lymphoma (B-NHL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.